Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination is a multispecies probiotic formulation composed of two *Lactobacillus* species and one *Bifidobacterium* species, designed to support gastrointestinal homeostasis and restore microbial balance. *Lactobacillus acidophilus* and *Lactobacillus casei* are resilient, lactic acid-producing bacteria that primarily colonize the small intestine, where they facilitate carbohydrate fermentation and inhibit the proliferation of pathogenic microorganisms through the production of organic acids and bacteriocins. *Bifidobacterium bifidum* is a key inhabitant of the large intestine, contributing to the maintenance of the mucosal barrier and the synthesis of essential B vitamins. Mechanistically, this combination acts via competitive exclusion for epithelial adhesion sites, nutrient competition, and signaling through pattern recognition receptors like Toll-like receptor 2 (TLR2) to modulate host immune responses and strengthen intestinal tight junctions. It is primarily indicated for the management of antibiotic-associated diarrhea, the alleviation of irritable bowel syndrome (IBS) symptoms, and the general restoration of the gut microbiome following dysbiosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus acidophilus + lactobacillus casei + bifidobacterium bifidum.